HOUSTON, Nov. 23, 2004 (PRIMEZONE) -- Dr. Stanislaw Burzynski, founder and Chairman of the Burzynski Research Institute, Inc. (BRI) (OTCBB:BZYR) in Houston, and his associates made two presentations on their research concerning the use of antineoplastons(R) A10 and AS2-1 in the treatment of brain tumors at the Ninth Annual Meeting of the Society for Neuro-Oncology, November 18-21 in Toronto, Canada.
The Society for Neuro-Oncology is a multidisciplinary organization dedicated to promoting advances in neuro-oncology through research and education. Founded in 1995, the Society now has members representing many areas of medical specialization, including epidemiology, medical oncology, neuro-oncology, neurosurgery, pathology, pediatrics, psychology, radiology, radiation oncology, and basic science.
In their presentation entitled "Phase II Study of Antineoplastons A10 and AS2-1 (ANP) In Recurrent Glioblastoma Multiforme," Dr. Burzynski and his colleagues described the exciting results from using ANP in treating 22 patients with glioblastoma multiforme (GBM), one of the deadliest brain tumors. Most of them had previous surgery and all had completed standard radiation therapy. Ten had also undergone chemotherapy. All were experiencing tumor recurrences. They received ANP intravenously and responses were assessed with MRI and PET images. The preliminary survival rate among these patients offers hope where none existed previously.
The second presentation, entitled "Long-Term Survivals In Phase II Studies of Antineoplastons A10 and AS2-1 (ANP) In Patients With Diffuse Intrinsic Brain Stem Glioma (DBSG)," dealt with research results from a group of 60 patients, 46 of whom had recurrent tumors after previous therapy and 14 had progressive DBSG without prior treatment. Patients with DBSG have a poor chance of survival , which has not changed substantially, despite various new treatments. Study results are showing that ANP compared favorably with standard radiation therapy (which offers less than a 10% survival rate at 2 years) and was not associated with serious adverse effects.
Antineoplastons(R) A10 and AS2-1 recently received the FDA's Orphan Drug Designation (O.D.D.) which is intended to encourage research, development and approval of products for diseases that affect fewer than 200,000 patients in the United States per year and provide a significant therapeutic advantage over existing treatments.
Burzynski Research Institute is a biopharmaceutical company committed to developing medicines for serious and life threatening diseases from genomics and naturally occurring compounds. Research and development efforts are focused on antineoplastons(R), autoimmune disease and HIV.
Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. BRI cautions investors not to place undue reliance on forward-looking statements contained in this press release. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to BRI's ability to obtain regulatory approval for antineoplastons(R) A10 and AS2-1. Receiving orphan drug designation does not increase the likelihood of eventual regulatory approval for a product candidate. BRI does not undertake to update any such forward- looking statements or to publicly announce developments or events relating to the matters described herein.
Company Logo URL for Burzynski Research Institute: http://www.primezone.com/newsroom/prs/?pkgid=1291